Finerenone improved heart failure outcomes compared with placebo in patients with CKD and T2D, with consistent benefits across baseline eGFR and UACR categories (all P interaction >0.10).
RCT
Does finerenone improve heart failure outcomes in patients with chronic kidney disease and type 2 diabetes across different eGFR and UACR categories?
Finerenone improves heart failure outcomes in patients with chronic kidney disease and type 2 diabetes consistently across various levels of kidney function and albuminuria.
BACKGROUND: In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration rate eGFR) and increasing albuminuria (urine albumin-to-creatinine ratio UACR). Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and T2D in FIDELITY (Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis). OBJECTIVES: This study sought to evaluate the effects of finerenone on HF outcomes by eGFR and/or UACR categories. METHODS: ) and/or UACR (0.10). CONCLUSIONS: Compared with placebo, finerenone improved HF-related outcomes in patients with CKD and T2D, with consistent benefits across eGFR and/or UACR categories. (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease FIDELIO-DKD, NCT02540993; Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Chronic Kidney Disease FIGARO-DKD, NCT02545049).
Filippatos et al. (2022) conducted an RCT in Chronic Kidney Disease and Type 2 Diabetes. Finerenone vs. Placebo was evaluated on Heart failure outcomes. Finerenone improved heart failure outcomes compared with placebo in patients with CKD and T2D, with consistent benefits across baseline eGFR and UACR categories (all P interaction >0.10).